check points when reviewing a genetic screening report

1. title and footnote, ensuring it describes the analysis population, the outcome variable and the class of genetic markers; 
2. eyeball examples:
• 1 example of x chr snp
• 1 example of autosomal snp with only 2 genotypes
• 1 example of top association 
• 1 example of a random association
3. use the excel output to check the value ranges for each column, pay attention to
• extreme values
• empty cells
• characters indicating missing: -,NA, 0
4. Cosmetic issues
• decimal places
• check line ends for character cut off

Prioritizing GWAS Results

This review paper mentioned 3 analytic methods to prioritizing GWAS results (for follow-up studies):

• Meta-analysis seeks to pool information from multiple GWAS to increase the chances of finding true positives among the false positives and provides a way to combine associations across GWAS, even when the original data are unavailable.

• Testing for epistasis within a single GWAS study can identify the stronger results that are revealed when genes interact.

• Pathway analysis of GWAS results is used to prioritize genes and pathways within a biological context. Following a GWAS, association results can be assigned to pathways and tested in aggregate with computational tools and pathway databases.

Biomarkers and surrogate endpoints

A good article discussing surrogate endpoints and the gap between scientific theory and clinical benefit.

famous patent law cases

The Supreme Court, In re Bilski and the Lingering Question of Labcorp v. Metabolite from patent docs.

Biotech and Pharma Provide Little Support in Bilski's Petition for Certiorari from Holman's Biotech IP blog.